• Home
  • GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis.

GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis.

Author List
Bruce SF, Cho K, Noia H, Lomonosova E, Stock EC, Oplt A, Blachut B, Mullen MM, Kuroki LM, Hagemann AR, McCourt CK, Thaker PH, Khabele D, Powell MA, Mutch DG, Shriver LP, Patti GJ, Fuh KC
Publication
Molecular cancer therapeutics
Publication ID (Profile URL)
https://researcherprofiles.org/profile/439145426
Publication Year
2022
PubMed ID
35588308
Publication Title
Bruce SF, Cho K, Noia H, Lomonosova E, Stock EC, Oplt A, Blachut B, Mullen MM, Kuroki LM, Hagemann AR, McCourt CK, Thaker PH, Khabele D, Powell MA, Mutch DG, Shriver LP, Patti GJ, Fuh KC. GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis. Mol Cancer Ther. 2022 08 02; 21(8):1348-1359.